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Introduction: Platelet activation and endothelium dysfunction are determinants of atherothrombosis in acute
coronary syndrome (ACS) patients. The aim of this study was to investigate the relationship between platelet
and endothelial cell activation markers and mortality in patients presenting with ACS.
Materials and Methods: Plasma levels of RANTES, Neutrophil Activating Protein-2 (NAP-2), Thrombospondin-
1 (TSP-1), Von Willebrand Factor (VWF), Von Willebrand Factor Propeptide (VWF:pp) and Osteoprotegerin
(OPG) were measured in a cohort study of 339 consecutive ACS patients who underwent percutaneous coronary
interevention (PCI). The primary endpoint was 4-year mortality.
Results: There were 46 deaths during the follow up. Median values of VWF (12.2 μg/mL versus 7.86 μg/mL, P=
0.001) and VWF:pp (7.34 nM versus 6.17 nM, P=0.011) were higher in non-survivors compared to survivors.
High levels of OPG were found in 37 patients: 27 of them were survivors (9.2%) and 10 were non-survivors
(21.7%, P=0.011). Kaplan-Meier estimates of mortality for VWF were 7.5% in the ﬁrst quartile (n=6 deaths),
12.2% in the second quartile (n=10 deaths), 11.2% in the third quartile (n=9 deaths) and 25% in the fourth quar-
tile (n=21 deaths) of VWF (P=0.004). There was a 27.8% of probability of mortality when high OPG was mea-
sured versus 12.4% when low OPG was measured (P=0.007). No relationship between baseline platelet
activation markers and mortality was found.
Conclusion: In patients with ACS undergoing PCI, increased chronic endothelial cell activation and dysfunction is as-
sociated with an increased risk of long-term mortality.© 2012 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Partial or total occlusion of a coronary artery, primarily by a
thrombus formed at the site of an atherosclerotic plaque is an
atherothrombotic event of considerable clinical importance. To pre-
vent a secondary event in these patients, anti-platelet therapy is
given as one of the key treatment options [1,2]. Nevertheless, mortal-
ity of patients with acute coronary syndrome (ACS) remains relative-
ly high [3,4]. Better characterization of ACS patients at high risk for
having a secondary event may help in the development of individual-
ly “tailored” therapies and thus improve survival.
The vascular endothelium is an important regulator of coronary
blood ﬂow [5] and it has been suggested that endothelial perturbation
predicts adverse clinical outcomes in patients with angina pectoris [6]
and acute myocardial infarction [7,8]. Von Willebrand Factor (VWF) is
a prominentmarker of endothelial perturbation and plays an importantUtrecht, Department of Clini-
aan 100, 3584 CX Utrecht, The
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.
 OA license.role in the interplay between platelets and the sub-endothelium. Upon
rupture of an atherosclerotic plaque, VWF is essential for platelet adhe-
sion, the ﬁrst step in thrombus formation and occlusion of a coronary
artery [9]. Physical evidence for involvement of VWF in platelet throm-
bus growth is provided by the detection of VWF in coronary thrombi
[10]. Under shear conditions, VWF supports the adhesion and rolling
of platelets on the endothelium [11,12]. Subsequently, platelets are ac-
tivated and platelet granule contents are released into the circulation.
The most abundant proteins released from platelet α-granules have
inﬂammatory and mitogenic properties [13]. As such, they enable the
migration of monocytes to the site of the inﬂammation, activate endo-
thelial cells and create a pro-coagulant environment [14]. Recently, it
has been suggested that in ACS patients, markers of endothelial pertur-
bation, with VWF in particular, are useful for detecting progression and
prognosis, while markers of coagulation and platelet activation are
valuable in aiding the treatment [12,15]. Beneﬁcial effects of therapies
improving endothelial function in preventing secondary events have
also been described [16–19].
In this prospective cohort study, we have investigated the relation of
platelet and endothelial cell activation markers to mortality in ACS pa-
tients. In total, 339 patients with conﬁrmed ACS were analyzed for six
Table 1
Demographic and Clinical Characteristics in Survivors and Non-Survivors.
Characteristic Survivors
(n=293)
Non-survivors
(n=46)
Age (years) 67.5 [59.5; 73.4] 76.8 [68.9; 83.4]⁎
Women 76 (25.9) 13 (28.3)
Body mass index (kg/m2) 26.8 [24.5; 29.4] 26.9 [24.7; 29.5]
Diabetes 64 (21.8) 18 (39.1)⁎
Arterial hypertension 179 (61.1) 29 (63.0)
Current smoker 50 (17.1) 9 (19.6)
Hypercholesterolemia (≥240 mg/dl) 207 (70.6) 28 (60.9)
C-reactive protein (mg/L) 3.6 [1.2; 10.3] 8.9 [2.5; 19.0]⁎
Serum creatinine (mg/dl) 1.0 [0.8; 1.1] 1.1 [1.0; 1.4]⁎
Systolic blood pressure (mmHg) 150.0 [130.0; 170.0] 150.0 [123.7; 170.5]
Diastolic blood pressure (mmHg) 70.0 [65.0; 80.0] 65.0 [60.0; 71.3]⁎
Malignancies 16 [5.5] 2 [4.3]
Peripherial artery disease 4 [1.4] 1 [2.2]
Chronic obstructive pulmonary
disease
6 [2.0] 4 [8.7]†
NYHA class†
I 173 (59.0) 18 (39.1)
II 102 (34.8) 21 (45.7)
III 13 (4.4) 5 (10.9)
IV 5 (1.8) 2 (4.3)
Therapy at discharge
Aspirin 293 (100.0) 45 (97.8)†
Thienopyridines 291 (99.3) 45 (97.8)
Statins 282 (96.3) 43 (93.5)
Beta-blockers 287 (98.0) 42 (91.3)†
ACE Inhibitors 268 (91.5) 42 (91.3)
Diuretics 105 (35.8) 26 (56.5)†
Calcium antagonists 13 (4.4) 5 (10.9)
Data are medians with 25th–75th percentiles or percentages.
⁎ Pb0.01.
† Pb0.05.
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of platelet activation. The other three: VWF, VWF:pp and OPG were
markers of endothelial activation.
Materials and methods
Patients
The study included 339 consecutive patients with ACS who
underwent PCI. Diagnosis of ACSwas established on the basis of charac-
teristics of anginal status, electrocardiographical and enzymatic criteria.
All patients had angiographically-proven coronary artery disease. An-
giographic diagnosis of coronary artery disease was based on the pres-
ence of coronary stenoses with≥75% lumen obstruction in at least 1 of
the 3 major coronary arteries. Antithrombotic treatment consisted of
clopidogrel (600 mg as a loading dose followed by 75 mg/day contin-
ued from at least 4 weeks up to 1 year) and aspirin (200 mg/day con-
tinued indeﬁnitely). Congestive heart failure was graded according to
the New York Heart Association (NYHA) classiﬁcation. Blood samples
were obtained at the time of admission and before angiography in all pa-
tients and collected into citrate anti-coagulated tubes.Within 30 min, the
bloodwas centrifuged at room temperature, and the plasma supernatant
was immediately aliquoted and stored frozen at −80 °C until analysis.
The study was conducted according to the principles of the Declaration
of Helsinki and approved by the institutional ethics committee. All pa-
tients gave informed consent for plasma collection and evaluation of
the biomarkers.
Antibodies
Antibodies against RANTES (MAB278, AB278NA), NAP-2 (MAB393,
BAF393), TSP-1(DY3074, BAF3074) and OPG (MAB8051, BAF805) were
purchased from R&D systems, Abbington, United Kingdom. Antibodies
against VWF (A0082, P0226) were purchased from DAKO, Denmark.
VWF:pp levels were measured using in-house polyclonal rabbit anti-
bodies raised as described earlier [20]. Bovine serum albumin (BSA)
was purchased from Sigma (A7906; Zwijndrecht, the Netherlands).
Supersignal ELISA pico chemiluminescent substrate was purchased
from Thermo Scientiﬁc, USA.
ELISAs
Levels of RANTES, NAP-2, TSP-1, VWF, VWF:pp and OPG were
measured using a semi-automated ELISA on a TECAN Freedom EVO
robot (Tecan, Switzerland). All of the antigens were measured on
separate 384 well Nunc maxisorp ELISA plates (Nunc, Denmark) in
one measurement for each individual marker. Capture antibodies,
MAB278 (0.5 μg/mL), MAB393 (1 μg/mL), DY3074 (0.5 μg/mL),
MAB8051 (1 μg/mL), A0082 (0.0775 μg/mL) and the home made an-
tibody against VWF:pp(5 μg/mL) were coated overnight at 4 °C.Wash-
ing with ﬁve steps of phosphate-buffered saline (PBS)/0.5%Tween
followed. Plasma samples were diluted 1/10 for RANTES, 1/80 for
NAP-2 1/15 for TSP-1, 1/625 for VWF, 1/20 for VWF:pp and 1/8 for
OPG. Every plate contained a 7 point calibration curve performed in
quadruple. Incubations were made in PBS/1%BSA for 2 h and un-
bound fractions were washed again with (PBS)/0.5%Tween ﬁve times.
Detection antibodies, AB-278-NA(1 μg/mL), BAF393(50 ng/mL), BAF3074-
(100 ng/mL), P0226(275 ng/mL), home made antibody against VWF:
pp(2.5 μg/mL) and BAF805(100 ng/mL) were added and washing as de-
scribed earlier followed. Relative light units from HRP activity were
measured with a chemiluminescent substrate (supersignal ELISA pico
chemiluminescent substrate, Thermo Scientiﬁc, USA) by Spectramax
reader (MDS Analytical Technologies). The lowest detection limit of
the ELISA for OPG was 0.035 ng/mL. Therefore, high levels of OPG
refer to values higher than 0.035 ng/mL.End-points and follow-up
The primary end point was all-cause mortality followed over a peri-
od of 4 years. Information on deaths was obtained from hospital re-
cords, death certiﬁcates, or telephone contact with relatives of the
patient or referring physician. Collection of baseline data and follow-
up information was performed by personnel blinded to clinical diagno-
sis or endothelial or platelet marker levels.
Statistical analysis
The distribution of the data was analyzed with the Kolmogorov–
Smirnov test. Categorical data were compared with the chi-square
test. Continuous data with skewed distribution were compared with
the Kruskal–Wallis rank-sum test. Survival analysis was performed by
applying the Kaplan-Meier method and differences in survival were
compared with the log-rank test. A multivariate Cox proportional haz-
ardsmodel was developed with variables in Table 1 that were regarded
as potential confounders. Correlation between various markers was
tested by calculating Spearman's correlation coefﬁcient. All analyses
were performed using S-plus statistical package (S-PLUS, Insightful
Corp., Seattle, Washington). All tests were two-tailed and P values less
than 0.05 were considered to indicate statistical signiﬁcance.
Results
Patient characteristics
Forty-six patients died during the 4-years of follow-up. There were
34 cardiac deaths and 12 non-cardiac deaths of which the causes were
the following: cancer (n=4), infections (n=4), stroke (n=3) and
chronic obstructive pulmonary disease (n=1). Demographic and clini-
cal characteristics of the survivors and non-survivors are shown in
Table 1. Angiographic characteristics are shown in Table 2. There were
Table 2
Angiographic Characteristics in Survivors and Non-Survivors.
Characteristic Survivors
(n=293)
Non-survivors
(n=46)
Number of narrowed coronary arteries
1 53 (18.1) 5 (10.9)
2 83 (28.3) 10 (21.7)
3 157 (53.6) 31 (67.4)
Multivessel disease 240 (81.9) 41 (89.1)
Lesion location
Left main coronary artery 20 (6.8) 4 (8.7)
Left anterior descending coronary artery 113 (38.6) 13 (28.3)
Left circumﬂex coronary artery 71 (24.2) 8 (17.4)
Right coronary artery 65 (22.2) 11 (23.9)
Venous bypass graft 11 (3.8) 6 (13.0)
Vessel size (mm) 2.98 [2.57; 3.40] 2.84 [2.52; 3.31]
Type of intervention
Stenting 266 (90.8) 36(78.3)
Balloon angioplasty 14(4.8) 6 (13.0)
Urgent CABG 7 (2.4) 4 (8.7)
Conservative 6 (2.0) 0
Data are medians with 25th–75th percentiles or percentages.
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gard to age, diabetes, C-reactive protein (CRP) level, serum creatinine,
diastolic blood pressure, chronic obstructive pulmonary disease, NYHA
class and therapy at discharge with aspirin, beta-blockers or diuretics.
Platelet markers and clinical outcome
Levels of RANTES, NAP-2 and TSP-1 were comparable between
the two groups and differences were not signiﬁcant (Table 3). There
was no association between the levels of platelet markers and mortality
(P=0.74 for association between RANTES level and mortality; P=0.91
for TSP-1; P=0.65 for NAP-2). As expected, platelet markers showed a
strong correlation with each other (Fig. 1).
Endothelial markers and clinical outcome
Distribution patterns of endothelial markers were evaluated with
the Kolmogorov-Smirnov test and none of them showed a normal
pattern. VWF correlated with CRP (Spearman R=0.3; Pb0.001) and
with VWF:pp (Spearman R=0.72; Pb0.001; Fig. 2).
Median values of VWF (12.2 μg/mL versus 7.86 μg/mL, P=0.001)
and VWF:pp (7.34 nM versus 6.17 nM, P=0.011) were higher in
non-survivors compared to survivors. Kaplan-Meier estimates of mor-
tality for VWF were 7.5% in the ﬁrst quartile (n=6 deaths), 12.2% in
the second quartile (n=10 deaths), 11.2% in the third quartile (n=9
deaths) and 25% in the fourth quartile (n=21 deaths) of VWF, showing
a signiﬁcant increase inmortality risk for patients in the highest quartile
of VWF versus the lower three quartiles (P=0.004; Fig. 3). High levels
of OPG were measured in 37 patients: 27 of them were survivorsTable 3
Endothelial and platelet biomarkers in Survivors and Non-Survivors.
Characteristic Survivors
(n=293)
Non-survivors
(n=46)
RANTES (ng/mL) 3.09 [1.15; 3.62] 2.74[0.84; 3.62]
NAP-2 (ng/mL) 8.73 [5.79; 13.79] 8.67 [4.83; 14.59]
TSP-1 (ng/mL) 231.2 [151.5; 358.0] 231.6 [162.3; 325.0]
VWF (μg/mL) 7.86 [4.97; 12.39] 12.20 [6.82; 18.76]⁎
VWF-pp (nM) 6.17 [5.08; 7.68] 7.34 [5.52; 9.34]†
High osteoprotegerin 27 (9.2%) 10 (21.7%)†
Data are medians with 25th–75th percentiles or percentages. 1 μg/mL of VWF corre-
sponds to 10 U/dL.
⁎ Pb0.01.
† Pb0.05.(9.2%) and 10 were non-survivors (21.7%, P=0.011; Table 3). High
OPG was also associated with a higher risk of mortality (P=0.007;
Fig. 4). Although a trend was observed, the association of VWF:pp in
quartiles to mortality did not reach statistical signiﬁcance (P=0.12).
A multivariate Cox proportional hazards model was used to assess
whether VWF correlates withmortality independently of potential con-
founders. After adjusting for age, sex, diabetes and CRP, VWF correlated
to mortality independently of other parameters (adjusted hazard ratio
[HR]=2.44, 95% CI 1.31–4.54), for 4th quartile versus the lower 3 quar-
tiles, P=0.005; Table 4). In the same model, VWF:pp was close to
reaching statistical signiﬁcance (adjusted HR=1.21, 95% CI 0.99–1.48,
P=0.066) while OPG was not a signiﬁcant correlate of mortality
(HR=1.56, 95% CI 0.75–3.24, P=0.229).
Discussion
The most important ﬁndings of the present study are: 1) Platelet
activation markers are not associated with long-term mortality in pa-
tients with ACS undergoing PCI and 2) Elevated levels of endothelial
markers at the time of the clinical presentation are associated with in-
creased risk of long-term mortality in these patients.
Platelet activation in relation to abnormal thrombogenesis has
been studied before in atrial ﬁbrillation [21] but to our knowledge,
the relationship of RANTES, NAP-2 and TSP-1 as platelet activation
markers to secondary manifestations of ACS has been barely investi-
gated [22]. Once released from activated platelets, RANTES binds the
endothelium where it enables the migration and arrest of monocytes
under ﬂow conditions [23]. This is important in atherogenic processes
such as neointima formation [24]. NAP-2 induces chemotaxis of
monocytes, neutrophils and neutrophil degranulation and increased
levels of this marker have been reported in patients with unstable
coronary artery disease [25]. Increased levels of NAP-2 s precursor
β-Thromboglobulin during acute myocardial infarction have been
reported since the early 80s [26–28], but its role in secondary mani-
festations of ACS has not been studied thoroughly. TSP-1 is a major
constituent of platelet α-granules, plasma levels of which increase
100-fold when platelets are activated [29] but its role in coronary ar-
tery disease has not been convincingly demonstrated. While correlat-
ing strongly with each other, our study shows that RANTES, NAP-2
and TSP-1 are not associated with mortality in patients with ACS. A
simple explanation might be that all patients with ACS are on
anti-platelet therapy [30–32]. An increased risk of mortality due to
hyper-reactive platelets could be efﬁciently neutralized by the use
of aspirin or clopidogrel. In line with this suggestion, a recent study
showed that clopidogrel treatment decreases RANTES secretion [33].
In one of the earlier studies in this ﬁeld, Montalescot et al. showed
that raised plasma levels of VWF are an independent predictor of ad-
verse clinical outcomes in unstable angina patients at 14 and 30 days
of follow up [34]. Raised levels of VWF in patients with angina were
shown to be prognostically valuable at an endpoint of 2 years also [6].
In both studies, higher VWF was thought to reﬂect endothelial pertur-
bation. The propeptide of VWF plays an important role on the
multimerization of VWF in endothelial cells but once in circulation, it
circulates separately from VWF and it has a much shorter half-life.
Due to the differences in half-life, the measurement of VWF and its
propeptide can be used to distinguish between acute and chronic endo-
thelial activation [35]. Accordingly, VWF:pp was reported to be in-
creased in acute vascular disorders such as septicemia and thrombotic
thrombocytopenic purpura, but onlymildly elevated in chronic vascular
disorders such as diabetes mellitus [36]. Although the predictive value
of VWF levels has been studied in coronary syndromes [6,7,34,37,38],
to our knowledge, the relationship of VWF together with VWF:pp in re-
lation to secondary manifestations of ACS has not been investigated
before.
In this study, we found that raised VWF levels are associated with
mortality in patients presenting with an ACS. Furthermore, we show
Fig. 1. Correlation between platelet activation markers; a) correlation between TSP-1 and Rantes; b) correlation between TSP-1 and NAP-2; c) correlation between NAP-2 and
Rantes; The correlation is quantiﬁed by the Spearman's correlation coefﬁcient (r).
201A. Hyseni et al. / Thrombosis Research 131 (2013) 198–203for the ﬁrst time, that in addition to increased VWF levels, high-risk
ACS patients have mildly increased levels of its propeptide. This indi-
cates that high-risk ACS patients are characterized by a chronic dys-
function of the endothelium.Fig. 2. Correlation between VWF and VWF:pp. The correlation is quantiﬁed the
Spearman's correlation coefﬁcient (r).The endothelium can be described as a dynamic endocrine organ
which is involved in controlling the vasomotor tone, transport
of nutrients and is metabolically very active. Its importance in
thrombosis and disturbed blood ﬂow is acknowledged for a long
time. A recent study by Kanaji et al. [39] involving knockout models
(VWF −/−) in mice expressing VWF only in endothelial cells orFig. 3. Kaplan-Meier curves of 4-year mortality according to VWF quartiles.
Fig. 4. Kaplan-Meier curves of 4-year mortality in patients with high-osteoprotegerin
versus those with no increase in the osteoprotegerin level.
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sufﬁcient to support hemostasis (in VWF−/−mice) and that VWF pro-
duced in megakaryocytes/platelets can also contribute to hemostasis in
the absence of endothelium-derived VWF. Clinically however, the im-
portance of the endothelium in the prevention of secondary events has
not been established yet unequivocally [15]. A relevant question in this
context iswhether the disruption of the endothelium is due to the infarct
related coronary artery or is a more generalized phenomenon. VWF did
not correlate with troponin I over the ﬁrst 48 h of hospitalization in a
study with unstable angina patients, indicating that the increase of
VWF corresponds to a mechanism of disease other than myocardial
cell damage [40].
The third protein localized in the endothelium that we have mea-
sured is OPG. OPG is a member of the tumor necrosis factor receptor
family and a soluble decoy receptor for the osteoclast differentiation
factor receptor-activator of nuclear factor κB ligand [41]. This path-
way has been implicated in various inﬂammatory responses and ath-
erogenesis. Furthermore, OPG serum levels were recently shown to
predict the incidence of cardiovascular disease in the general popula-
tion [42] and mortality in ACS patients [43]. Of importance in relation
to our study, OPG is localized together with VWF and VWF:pp in the
Weibel-Palade bodies of the endothelium [44] and might play a role
in vascular injury [45]. We observed high levels of OPG in 37 of the
patients included in this study. Interestingly, non-survivors were
more likely to have higher OPG levels than survivors (Table 3).
Our study has some limitations. We could not estimate absolute
values of OPG on the majority of the samples of the study as they
were below the detection limit. While the patient population of our
study is larger than most of the earlier studies on the prognostic
value of VWF [7,34,37,38,46], it is still underpowered to reach a ﬁrm
conclusion. Another limitation of our study which remains to be re-
solved in future studies is the role of active VWF in ACS patients un-
dergoing PCI. Lastly, in this population, aggregation tests to measure
the degree of the effectiveness of the anti-platelet therapy were not
performed. However, strong points of our study include the use of aTable 4
Multivariate Cox proportional hazards model regarding 4-year all-cause
mortality adjusted for age, sex, CRP and Diabetes.
Characteristic Hazard Ratio [95%
conﬁdence interval]
VWF (quartile 4 vs.
the lower three)
2.44 [1.31–4.54]⁎
VWF-propeptide 1.21 [0.99–1.48]
Osteoprotegerin 1.56 [0.75–3.24]
⁎ Pb0.01.combination of markers to asses the role of platelets and the endothe-
lium, a well-characterized sample of patients with ACS, a long follow
up of 4 years and mortality as an endpoint.
In conclusion, our ﬁndings show that in ACS patients, chronic en-
dothelial activation is associated with a poor prognosis. We did not
ﬁnd an association of platelet activation markers and mortality,
which supports the notion that, markers of platelet activation are
more valuable in guiding the treatment than to predict prognosis.
Pharmacological targeting of the endothelium in ACS patients de-
serves further careful attention.
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